Phase 1/Pilot Consortium 2015 ADVL1011 – Ruxolitinib Loh ML, Tasian SK, Rabin KR, Brown PA, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 May 13 [Epub ahead of print]. PMCID: PMC Journal - In Process. ADVL1014 – Reolysin Kolb EA, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe T, Hingorani P, Ahern CH, Weigel BJ, Zwiebel J, Blaney SM. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer. 2015 May;62(5):751-8. PMCID: PMC4376570. ADVL0911 – Seneca Valley Virus (NTX-010) Burke MJ, Ahern CH, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt M, Blaney SM. Phase 1 trial of seneca valley virus (NTX-010) in children with relapsed / refractory solid tumors: A report of the Children's Oncology Group. Pediatr Blood Cancer. 2015 May;62(5):743- 50. PMCID: PMC4376652. ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus (CCI-779) Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern CH, Thomas G, Mercer C, Krueger DA, Houghton PJ, Doyle A, Chen H, Weigel BJ, Blaney SM. A Phase I study of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium report. Clin Cancer Res. 2015 Apr 1;21(7):1558-65. PMCID: PMC4454739. ADVL1114 – Temsirolimus (CCI-779) with Intensive Re-induction Abstract Rheingold S, Whitlock J, Tasian S, Teachey D, Borowitz M, Liu X, Ahern CH, Minard CG, Fox E, Weigel BJ, Blaney SM. Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): a Children’s Oncology Group study. 2015 ASCO Annual Meeting. J Clin Oncol; 33(15s): abstr 10029. ADVL1212 – Crizotinib with Conventional Chemotherapy Abstract Greengard E, Mosse Y, Liu X, Ahern CH, Minard CG, Blaney SM, Fox E, Weigel BJ. A Safety and tolerability of crizotinib in combination with chemotherapy for relapsed or refractory solid tumors or anaplastic large cell lymphoma: a Children’s Oncology Group phase I consortium study. 2015 ASCO Annual Meeting. J Clin Oncol; 33(15s): abstr 10058. Phase 1/Pilot Consortium ADVL1213 – Ontuxizumab (MORAb-004) Abstract Norris RE, Fox E, Reid JM, Ralya AT, Liu X, Ahern CH, Minard CG, Dahl J, Eubank R, Weigel BJ. Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study. 2015 ASCO Annual Meeting. J Clin Oncol; 33(15s): abstr 10036. AHOD1221 – Brentuximab Vedotin + Gemcitabine Abstract Cole PD, Metzger M, Drachtman RA, Horton TM, Liu X, Ahern CH, Minard CG, Fox E, Blaney SM, Weigel BJ, Kelly K. Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report. 2015 ASCO Annual Meeting. J Clin Oncol; 33(15s): abstr 8544. Phase 1/Pilot Consortium 2014 ADVL0918 – Temsirolimus + Irinotecan and Temozolomide Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. Pediatr Blood Cancer. 2014 May;61(5):833-9. PMCID: PMC4196713. ADVL1013 – MK-2206 Fouladi M(1), Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM. A phase I trial of MK-2206 in children with refractory malignancies: A children's oncology group study. Pediatr Blood Cancer. 2014 Jul;61(7):1246-51. PMCID: PMC4456022. ADVL1011 – Ruxolitinib Abstract Tasian SK, Loh ML, Rabin KR, Brown PA, Ahern CH, Weigel BJ, Blaney SM. A Phase I Study of Ruxolitinib in Children with Relapsed/Refractory Solid Tumors, Leukemias, or Myeloproliferative Neoplasms: A Children’s Oncology Group Phase I Consortium Study (ADVL1011). 2014 ASCO Annual Meeting. J Clin Oncol; 32(15s): abstr 10019. ADVL1111 – Tivantinib (ARQ 197) Abstract Geller J, Perentesis JP, Ahern CH, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND#112603) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study. 2014 ASCO Annual Meeting. J Clin Oncol; 32(15s): abstr 2627. ADVL1211 – Cabozantinib (XL184) Abstract Chuk MK, Widemann BC, Ahern CH, Reid JM, Kim A, Wright JJ, Lodish MB, Fox E, Weigel BJ, Blaney SM. A phase I study of Cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group Phase I Consortium Trial. 2014 ASCO Annual Meeting. J Clin Oncol; 32(15s): abstr 10078. Phase 1/Pilot Consortium 2013 ADVL1112 – Imetelstat Thompson PA, Drissi R, Muscal J, Panditharatna EA, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM. A Phase 1 trial of imetelstat in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1112). 2013 Dec 1;19(23):6578-6584. PMCID: PMC4079262. ADVL0912 – Crizotinib Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis, F, Maris JM, Weigel BJ, Ingle AM, Ahern CH, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol; 2013 May; 14(6):472-480. PMCID: PMC3730818. ADVL0819 – Vorinostat and Temozolomide in CNS Tumors Hummel TR, Wagner LM, Ahern CH, Fouladi M, Reid JM, McGovern R, Ames MM, Gilbertson RJ, Horton TM, Ingle AM, Weigel BJ, Blaney SM. A pediatric phase 1 Trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase 1 Consortium study. Pediatr Blood Cancer; 2013 Sep; 60(9):1452-1457. PMCID: PMC4139006. ADVL0815 – Pazopanib Glade Bender JL, Lee A, Reid JM, Baruchel S, Roberts T, Voss SD, Wu B, Ahern CH, Ingle AM, Harris P, Weigel BJ, Blaney SM. A Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: A Children's Oncology Group Phase I consortium report. J Clin Oncol; 2013 Aug; 31(24):3034-3043. PMCID: PMC3739862. ADVL0911 – Seneca Valley Virus (NTX-010) Abstract Burke MJ, Ahern CH, Weigel BJ, Ingle AM, Cripe TP, Bernhardt M, Blaney SM. A phase I study of seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors (ADVL0911): A report of the Children's Oncology Group. Presented at: The Seventh International Meeting On Replicating Oncolytic Virus Therapeutics; 2013 June 15-18; Montreal, Canada. Phase 1/Pilot Consortium ADVL1014 – Reolysin Abstract Kolb EA, Sampson V, Stabley D, Walter A, Cripe TP, Hingorani P, Ahern CH, Ingle AM, Weigel BJ, Blaney SM. A Phase I trial and Viral Clearance Study of Reovirus (Reolysin) in Children with Relapsed or Refractory Extra-cranial Solid Tumors: A Children’s Oncology Group Phase I Consortium Report. Poster presented at: AACR-Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes Conference; 2013 November 3-6; San Diego, CA. ADVL1115 – Trebananib (AMG386) Abstract Leary SE, Park JR, Reid JM, Ralya A, Baruchel S, Wu B, Ingle AM, Ahern CH, Weigel BJ, Blaney SM. A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report. 2013 ASCO Annual Meeting. J Clin Oncol; 2013 May; 31(15 suppl):abstr 2538. Phase 1/Pilot Consortium 2012 ADVL0916 - Vorinostat and Bortezomib Muscal J, Horton TM, Ingle AM, Ahern CH, McGovern R, Reid JM, Ames MM, Espinoza- Delgado I, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase 1 consortium study (ADVL0916). Pediatr Blood Cancer; 2012 Nov; 60(3):390-395. PMCID: PMCID3511610. ADVL0812 - MLN8237 Mossé, YP, Lipsitz EG, Teachey DT, Maris JM, Weigel BJ, Adamson PC, Ingle AM, Ahern CH, Blaney SM. Pediatric phase 1 trial and pharmacokinetic study of MLN8237, an investigational oral selective small molecule inhibitor of aurora kinase A: A Children's Oncology Group Phase 1 Consortium study. Clin Cancer Res; 2012 Nov; 18(21):6058-6064. PMCID: PMC4008248. ADVL0714 - VEGF Trap Glade Bender JL, Blaney SM, Borinstein SC, Reid JM, Baruchel S, Ahern CH, Ingle AM, Yamashiro DJ, Chen A, Weigel BJ, Adamson PC, Park JR. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: A Children’s Oncology Group Phase I consortium report. Clin Cancer Res; 2012 Sep; 18(18):5081-5089. PMCID: PMC3445751. ADVL0712 – Cixutumumab (IMC-A12) Malempati S, Weigel BJ, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo M, Adamson PC, Blaney SM. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol; 2012 Jan; 30(3):256-262. PMCID: PMC3269952. ADVL0612 – Sunitinib Pharmacokinetics DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade Bender JL, Ivy SP, Adamson PC, Blaney SM, DuBois JJ. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: A Children's Oncology Group study. Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-1027. PMCID: PMC3149978. ADVL0413 – Sorafenib Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender JL, Burke MJ, Weigel BJ, Stempak D, Balis FM, Blaney SM. A Phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or refractory leukemias: A Children's Oncology Group Phase I Consortium report. Clin Cancer Res; 2012 Nov; 18(21):6011-6022. PMCID: PMC4008314. Phase 1/Pilot Consortium ADVL1013 – MK 2206 Abstract Phillips C, Fouladi M, Perentesis JP, Leary SE, McGovern R, Reid JM, Ingle AM, Ahern CH, Ames MM, Houghton PJ, Doyle A, Weigel BJ, Blaney SM. A phase I trial of MK 2206 in children with refractory solid tumors: A Children's Oncology Group study. 2012 ASCO Annual Meeting. J Clin Oncol; 2012 May; 30(15 suppl):abstr 9581. ADVL0918 – Temsirolimus + Irinotecan and Temozolomide Abstract Bagatell R, Norris RE, Ingle AM, Ahern CH, Saggio JN, Little AR, Weigel BJ, Blaney SM. Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study. 2012 ASCO Annual Meeting. J Clin Oncol; 2012 May; 30(15 suppl):abstr 9540. ADVL0912 – Crizotinib Abstract Mossé, YP, Balis FM, Lim MS, Blaney SM, Voss SD, Fox EJ, Bagatell R, Weigel BJ, Adamson PC, Ingle AM, Ahern CH, Laliberte J. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. 2012 ASCO Annual Meeting. J Clin Oncol; 2012 May; 30(15 suppl):abstr 9500. ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus Abstract Fouladi M, Perentesis JP, Wagner LM, Ingle AM, Thomas GA, Krueger DA, Houghton P, Vinks AA, Doyle LA, Weigel BJ, Blaney SM. A phase I trial of IMC A12 and temsirolimus in children with refractory solid tumors: A Children’s Oncology Group study. 2012 ASCO Annual Meeting. J Clin Oncol; 2012 May; 30(15 suppl):abstr 9541. Phase 1/Pilot Consortium 2011 ADVL0612 - Sunitinib DuBois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade Bender JL, Ivy SP, Grier HE, Adamson PC, Blaney SM. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A Children’s Oncology Group study. Clin Cancer Res; 2011 Aug; 17(15):5113-5122. PMCID: PMC3149978. ADVL0516 – Dasatinib Aplenc R, Blaney S, Strauss LC, Balis FM, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright J, Adamson PC. Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the Children's Oncology Group Phase I Consortium. J Clin Oncol; 2011 Mar; 29(7):839-844. PMCID: PMC3068059. ADVL0516 – Dasatinib Correlative study Guerrouahen BS, Wieder E, Blanchard EG, Lee FY, Aplenc R, Corey S. Flow Cytometric Determination of Src Phosphorylation in Pediatric Patients Treated With Dasatinib. Pediatr Blood Cancer; 2009 Dec; 53(6):1132-1135. PMCID: PMC2760231. ADVL0515 –Vinblastine + Carboplatin in Low Grade Glioma Jakacki RI, Bouffet E, Adamson PC, Ingle AM, Voss SD, Blaney SM. A Phase I Study Of Vinblastine In Combination With Carboplatin For Children With Low-Grade Gliomas: A Children’s Oncology Group Phase 1 Consortium Study. Neuro-oncol; 2011 Aug; 13(8):910-915. PMCID: PMC3145477. ADVL0419 – Valproic Acid Su JM, Li X, Thompson PA, Ou C, Ingle AM, Russell HV, Lau CC, Adamson PC, Blaney SM. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A Children's Oncology Group report. Clin Cancer Res; 2011 Feb; 17(3):589-597. PMCID: PMC3064523. ADVL0319 – Lenalidomide Berg S, Cairo M, Russell HV, Ayello J, Ingle AM, Lau H, Chen N, Adamson P, Blaney S. Safety, pharmacokinetics and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: A Children's Oncology Group Phase I Consortium report. J Clin Oncol; 2011 Jan; 29(3):316-323. PMCID: PMC3056465. ADVL0116 – Tipifarnib Widemann B, Arceci R, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright J, Blaney S, Adamson P, Balis F. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children’s Oncology Group. Pediatr Blood Cancer; 2011 Feb; 56(2):226-233. PMCID: PMC3271115. Phase 1/Pilot Consortium ADVL0916 – Vorinostat and Bortezomib Abstract Muscal J, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern R, Reid JM, Ames MM, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group study. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 May; 29(15 suppl):abstr 9522. ADVL0819 – Vorinostat and Temozolomide Abstract Hummel TR, Wagner LM, Ahern CH, McGovern R, Ames MM, Gilbertson RJ, Horton TM, Ingle AM, Weigel BJ, Blaney SM. A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children’s Oncology Group Phase I Consortium Study. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 May; 29(15 suppl):abstr 9579. ADVL0815 – Pazopanib Abstract Glade Bender JL, Lee A, Adamson PC, Ingle AM, Ahern CH, Wu B, Baruchel S, Harris PJ, Ames MM, Weigel BJ, Blaney SM. Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 Jun; 29(15 suppl):abstr 9501. ADVL0815 – Pazopanib Abstract Glade Bender JL, Khrichenko D, Voss SD, Lee A, Ingle AM, Ahern CH, Weigel BJ, Blaney SM, Roberts T. An expanded imaging cohort of pazopanib in children and adolescents with relapsed or refractory soft tissue sarcoma (ADVL0815): A Children's Oncology Group phase I consortium trial. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Mol Cancer Ther; 2011 Nov; 10(11 suppl):abstr nr C108. ADVL0813 – Cixutumumab (IMC-A12) + Temsirolimus Abstract Fouladi M, Perentesis JP, Wagner LM, Ingle AM, Gammon J, Thomas G, Krueger DA, Houghton P, Vinks S, Weigel BJ, Blaney S. A phase I trial of IMC-A12 and temsirolimus in children with refractory solid tumors: A Children's Oncology Group Study. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 May; 29(15 suppl):abstr 9520. ADVL0612 – Sunitinib Abstract DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade-Bender J, Ivy P, Grier H, Adamson PC, Blaney SM. Tolerability and Pharmacokinetic Profile of Sunitinib Given as a Powder Formulation to Children with Refractory Solid Tumors: A Children’s Oncology Group Study. In: 43rd Congress of the International Society of Paediatric Oncology (SIOP) 2011 Auckland, New Zealand, 28th–30th October, 2011, SIOP Abstracts. Pediatr Blood Cancer; 2011 Nov; 57(5): 717-718, Oral Presentation #O042. Phase 1/Pilot Consortium Phase 1 Correlatives Studies - Antiangiogenesis Biomarkers Abstract Baruchel S, Wu B, Mokhtari RB, Glade Bender JL, DuBois SG, Widemann BC, Park JR, Stempak D, Ahern CH, Weigel BJ. Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. 2011 ASCO Annual Meeting. J Clin Oncol; 2011 May; 29(15 suppl):abstr 9502.